Cargando…

Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease

Neuromuscular disorders such as Duchenne Muscular Dystrophy and Spinal Muscular Atrophy are neurodegenerative genetic diseases characterized primarily by muscle weakness and wasting. Until recently there were no effective therapies for these conditions, but antisense oligonucleotides, a new class of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sardone, Valentina, Zhou, Haiyan, Muntoni, Francesco, Ferlini, Alessandra, Falzarano, Maria Sofia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154734/ https://www.ncbi.nlm.nih.gov/pubmed/28379182 http://dx.doi.org/10.3390/molecules22040563

Ejemplares similares

Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases
por: Verma, Ashok
Publicado: (2018)

A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures
por: Hiller, Monika, et al.
Publicado: (2018)

The authors reply: Letter on: "Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy" by Zhou et al.
por: Zhou, Haiyan, et al.
Publicado: (2020)

Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide Therapy
por: Catapano, Francesco, et al.
Publicado: (2016)

Urinary Stem Cells as Tools to Study Genetic Disease: Overview of the Literature
por: Falzarano, Maria Sofia, et al.
Publicado: (2019)

Antisense Oligonucleotide-Based Therapy of Viral Infections
por: Tarn, Woan-Yuh, et al.
Publicado: (2021)

Gapmer Antisense Oligonucleotides Suppress the Mutant Allele of COL6A3 and Restore Functional Protein in Ullrich Muscular Dystrophy
por: Marrosu, Elena, et al.
Publicado: (2017)

Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
por: Zhou, Haiyan, et al.
Publicado: (2020)

Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment
por: Sintusek, Palittiya, et al.
Publicado: (2016)

Duchenne Muscular Dystrophy: From Diagnosis to Therapy
por: Falzarano, Maria Sofia, et al.
Publicado: (2015)

Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases
por: Giudice, Valentina, et al.
Publicado: (2020)

The potential of antisense oligonucleotide therapies for inherited childhood lung diseases
por: Martinovich, Kelly M., et al.
Publicado: (2018)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Cerebral Organoids and Antisense Oligonucleotide Therapeutics: Challenges and Opportunities
por: Lange, Jenny, et al.
Publicado: (2022)

Antisense Oligonucleotides as a Novel Therapy for Cushing’s Disease
por: Eltumi, Hanan, et al.
Publicado: (2021)

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
por: Gagliardi, Maria, et al.
Publicado: (2021)

Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023)

A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
por: Kim, Kyuho, et al.
Publicado: (2022)

Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement
por: Batista-Duharte, Alexander, et al.
Publicado: (2020)

Improved Antisense Oligonucleotide Design to Suppress Aberrant SMN2 Gene Transcript Processing: Towards a Treatment for Spinal Muscular Atrophy
por: Mitrpant, Chalermchai, et al.
Publicado: (2013)

Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases
por: Aoki, Yoshitsugu, et al.
Publicado: (2021)

Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy
por: Fortunato, Fernanda, et al.
Publicado: (2021)

Antisense oligonucleotide therapy for KCNT1 encephalopathy
por: Burbano, Lisseth Estefania, et al.
Publicado: (2022)

Selective Neuromuscular Denervation in Taiwanese Severe SMA Mouse Can Be Reversed by Morpholino Antisense Oligonucleotides
por: Lin, Te-Lin, et al.
Publicado: (2016)

Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's Disease
por: Stoker, Thomas B., et al.
Publicado: (2020)

Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic
por: Rook, Morgan E., et al.
Publicado: (2022)

Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm
por: Grabowska-Pyrzewicz, Wioleta, et al.
Publicado: (2021)

Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides
por: Goyenvalle, Aurelie, et al.
Publicado: (2016)

Nonviral delivery systems for antisense oligonucleotide therapeutics
por: Huang, Si, et al.
Publicado: (2022)

Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides
por: Goyenvalle, Aurélie, et al.
Publicado: (2023)

RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
por: Bajan, Sarah, et al.
Publicado: (2020)

mRNA in situ hybridization exhibits unbalanced nuclear/cytoplasmic dystrophin transcript repartition in Duchenne myogenic cells and skeletal muscle biopsies
por: Falzarano, Maria Sofia, et al.
Publicado: (2023)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy
por: Aoki, Yoshitsugu, et al.
Publicado: (2013)

Advances of Antisense Oligonucleotide Technology in the Treatment of Hereditary Neurodegenerative Diseases
por: Lin, Mengsi, et al.
Publicado: (2021)

The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases
por: Ulanova, Marina, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_b1jlbnugf7kd7r3a5ivjm190r2